Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The companys product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: N/A
- Symbol: NASDAQ:TNXP
- CUSIP: N/A
- Web: www.tonixpharma.com
Capitalization:- Market Cap: $31.16 million
- Outstanding Shares: 7,508,000
Average Prices:- 50 Day Moving Avg: $3.66
- 200 Day Moving Avg: $3.84
- 52 Week Range: $0.33 - $9.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.80
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $4.53 per share
- Price / Book: 0.92
Profitability:- EBIDTA: ($24,360,000.00)
- Return on Equity: -84.89%
- Return on Assets: -78.71%
Debt:- Current Ratio: 19.39%
- Quick Ratio: 19.39%
Misc:- Average Volume: 112,373 shs.
- Beta: 2.86
- Short Ratio: 7.49
Frequently Asked Questions for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
What is Tonix Pharmaceuticals Holding Corp.'s stock symbol?
Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ under the ticker symbol "TNXP."
How were Tonix Pharmaceuticals Holding Corp.'s earnings last quarter?
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.78) by $0.13. View Tonix Pharmaceuticals Holding Corp.'s Earnings History.
When will Tonix Pharmaceuticals Holding Corp. make its next earnings announcement?
Where is Tonix Pharmaceuticals Holding Corp.'s stock going? Where will Tonix Pharmaceuticals Holding Corp.'s stock price be in 2017?
5 brokerages have issued twelve-month price objectives for Tonix Pharmaceuticals Holding Corp.'s shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Tonix Pharmaceuticals Holding Corp.'s share price to reach $8.33 in the next twelve months. View Analyst Ratings for Tonix Pharmaceuticals Holding Corp..
Who are some of Tonix Pharmaceuticals Holding Corp.'s key competitors?
Some companies that are related to Tonix Pharmaceuticals Holding Corp. include Concordia International Corp. (CXRX), Flex Pharma (FLKS), Egalet Corporation (EGLT), TRACON Pharmaceuticals (TCON), SCYNEXIS (SCYX), Endocyte (ECYT), Chiasma (CHMA), vTv Therapeutics (VTVT), The Joint Corp. (JYNT), Infinity Pharmaceuticals (INFI), Cancer Genetics (CGIX), Dipexium Pharmaceuticals (PLXP), Trillium Therapeutics (TRIL), KemPharm (KMPH), Evoke Pharma (EVOK), Leap Therapeutics (LPTX), Xenon Pharmaceuticals (XENE) and OvaScience (OVAS).
Who owns Tonix Pharmaceuticals Holding Corp. stock?
Tonix Pharmaceuticals Holding Corp.'s stock is owned by a number of of retail and institutional investors. Top institutional shareholders include B. Riley Financial Inc. (5.05%), Vanguard Group Inc. (2.46%), Susquehanna International Group LLP (1.20%) and Kingdon Capital Management L.L.C. (0.86%). Company insiders that own Tonix Pharmaceuticals Holding Corp. stock include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals Holding Corp..
Who sold Tonix Pharmaceuticals Holding Corp. stock? Who is selling Tonix Pharmaceuticals Holding Corp. stock?
Who bought Tonix Pharmaceuticals Holding Corp. stock? Who is buying Tonix Pharmaceuticals Holding Corp. stock?
Tonix Pharmaceuticals Holding Corp.'s stock was purchased by a variety of institutional investors in the last quarter, including B. Riley Financial Inc. and Vanguard Group Inc.. Company insiders that have bought Tonix Pharmaceuticals Holding Corp. stock in the last two years include Bradley Saenger, Bruce Daugherty, Ernest Mario, Gregory M Sullivan, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals Holding Corp..
How do I buy Tonix Pharmaceuticals Holding Corp. stock?
Shares of Tonix Pharmaceuticals Holding Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals Holding Corp.'s stock price today?
One share of Tonix Pharmaceuticals Holding Corp. stock can currently be purchased for approximately $4.15.
MarketBeat Community Rating for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals Holding Corp. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $8.33 (100.80% upside) |
Analysts' Ratings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/23/2017 | Dawson James | Reiterated Rating | Buy | $9.00 | Medium |  |
| 8/22/2017 | Drexel Hamilton | Initiated Coverage | Buy | | High | |
| 8/18/2017 | Roth Capital | Upgrade | Neutral -> Buy | $6.00 | High | |
| 6/26/2017 | Aegis | Initiated Coverage | Buy | $10.00 | High | |
| 12/20/2016 | Oppenheimer Holdings, Inc. | Reiterated Rating | Hold | | N/A | |
| 9/7/2016 | Cantor Fitzgerald | Downgrade | Buy -> Hold | | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)Earnings History by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.69) | | | | | N/A | |
| 8/14/2017 | Q2 2017 | ($0.78) | ($0.65) | | | View | N/A | |
| 5/15/2017 | Q1 2017 | ($1.36) | ($1.27) | | | View | N/A | |
| 11/10/2016 | Q3 2016 | ($0.34) | ($0.29) | | | View | N/A | |
| 5/9/2016 | Q1 | ($0.63) | ($0.74) | | | View | N/A | |
| 3/4/2016 | Q4 | ($0.66) | ($0.71) | | | View | N/A | |
| 8/10/2015 | Q215 | ($0.65) | ($0.73) | | | View | N/A | |
| 5/11/2015 | Q115 | ($0.54) | ($0.71) | | | View | N/A | |
| 3/3/2015 | Q414 | ($0.81) | ($0.83) | | | View | N/A | |
| 11/10/2014 | Q314 | ($0.69) | ($0.71) | | | View | N/A | |
| 8/8/2014 | Q214 | ($0.53) | ($0.61) | | | View | N/A | |
| 5/13/2014 | Q114 | ($0.35) | ($0.59) | | | View | N/A | |
| 3/31/2014 | | ($0.46) | ($0.74) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)2017 EPS Consensus Estimate: ($2.79)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.83) | ($0.83) | ($0.83) |
| Q2 2017 | 1 | ($0.69) | ($0.69) | ($0.69) |
| Q3 2017 | 1 | ($0.65) | ($0.65) | ($0.65) |
| Q4 2017 | 1 | ($0.62) | ($0.62) | ($0.62) |
(Data provided by Zacks Investment Research)
Dividend History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 28.27%
Insider Trades by Quarter for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/17/2017 | Seth Lederman | CEO | Buy | 20,000 | $3.00 | $60,000.00 | |
| 6/30/2017 | Ernest Mario | Director | Sell | 6,105 | $4.28 | $26,129.40 | |
| 6/30/2017 | Seth Lederman | CEO | Buy | 5,000 | $4.33 | $21,650.00 | |
| 6/26/2017 | Seth Lederman | CEO | Buy | 5,000 | $4.40 | $22,000.00 | |
| 6/20/2017 | Seth Lederman | CEO | Buy | 20,000 | $4.22 | $84,400.00 | |
| 11/23/2016 | Ernest Mario | Director | Buy | 120,000 | $0.41 | $49,200.00 | |
| 9/13/2016 | Ernest Mario | Director | Buy | 100,000 | $0.79 | $79,000.00 | |
| 6/22/2016 | Seth Lederman | CEO | Buy | 20,000 | $2.08 | $41,600.00 | |
| 6/21/2016 | Bradley Saenger | CFO | Buy | 2,000 | $2.00 | $4,000.00 | |
| 6/21/2016 | Bruce Daugherty | Insider | Buy | 100,000 | $2.00 | $200,000.00 | |
| 6/21/2016 | John B Rhodes | Director | Buy | 25,000 | $2.00 | $50,000.00 | |
| 6/3/2016 | Gregory M Sullivan | Insider | Buy | 20,000 | $2.50 | $50,000.00 | |
| 5/12/2016 | Ernest Mario | Director | Buy | 31,042 | $2.30 | $71,396.60 | |
| 5/11/2016 | Ernest Mario | Director | Buy | 8,210 | $2.24 | $18,390.40 | |
| 3/23/2016 | Seth Lederman | CEO | Buy | 8,000 | $2.44 | $19,520.00 | |
| 3/16/2016 | Ernest Mario | Director | Buy | 75,000 | $2.29 | $171,750.00 | |
| 9/30/2015 | Gregory M Sullivan | Insider | Buy | 5,000 | $5.18 | $25,900.00 | |
| 9/28/2015 | Gregory M Sullivan | Insider | Buy | 4,694 | $5.95 | $27,929.30 | |
| 9/25/2015 | Seth Lederman | CEO | Buy | 6,000 | $6.50 | $39,000.00 | |
| 8/26/2015 | Ernest Mario | Director | Buy | 10,000 | $6.05 | $60,500.00 | |
| 8/25/2015 | Ernest Mario | Director | Buy | 1,468 | $6.40 | $9,395.20 | |
| 8/24/2015 | Ernest Mario | Director | Buy | 2,532 | $6.20 | $15,698.40 | |
| 8/20/2015 | Ernest Mario | Director | Buy | 6,000 | $6.64 | $39,840.00 | |
| 8/17/2015 | Ernest Mario | Director | Buy | 15,000 | $6.93 | $103,950.00 | |
| 7/17/2015 | John B Rhodes | Director | Buy | 6,000 | $7.50 | $45,000.00 | |
| 7/17/2015 | Leland Gershell | CFO | Buy | 1,000 | $7.50 | $7,500.00 | |
| 6/11/2015 | Gregory M Sullivan | Insider | Buy | 4,500 | $8.38 | $37,710.00 | |
| 3/17/2015 | Seth Lederman | CEO | Buy | 2,000 | $7.02 | $14,040.00 | |
| 3/13/2015 | Seth Lederman | CEO | Buy | 2,000 | $7.24 | $14,480.00 | |
| 3/11/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.95 | $13,900.00 | |
| 3/10/2015 | Charles E Iv Mather | Director | Buy | 1,000 | $6.80 | $6,800.00 | |
| 3/9/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.48 | $12,960.00 | |
| 3/6/2015 | Ernest Mario | Director | Buy | 4,000 | $6.57 | $26,280.00 | |
| 3/5/2015 | Seth Lederman | CEO | Buy | 2,000 | $6.27 | $12,540.00 | |
| 2/9/2015 | Ernest Mario | Director | Buy | 30,000 | $5.85 | $175,500.00 | |
| 2/9/2015 | Leland Gershell | CFO | Buy | 5,000 | $5.85 | $29,250.00 | |
| 9/27/2013 | Charles E Iv Mather | Director | Buy | 1,000 | $3.65 | $3,650.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
Latest Headlines for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)
| Source: |
|
Tonix Pharmaceuticals Holding Corp. (TNXP) Chart for Monday, September, 25, 2017
